Alembic Pharmaceuticals Receives FDA Approval for Generic Valganciclovir Oral Solution

The U.S. FDA has granted final approval to Alembic Pharmaceuticals Limited for a 50 mg/mL valganciclovir oral solution, a generic equivalent to Valcyte. This approval provides a new treatment option for managing CMV retinitis in AIDS patients and preventing CMV disease in transplant recipients, potentially lowering prescription drug costs.